# Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

> **NCT02117362** · PHASE1 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** 1 mg/kg GR-MD-02
- **BIOLOGICAL:** 2 mg/kg GR-MD-02
- **BIOLOGICAL:** 4 mg/kg GR-MD-02
- **BIOLOGICAL:** 8 mg/kg GR-MD-02
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT02117362
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-08
- **Primary completion:** 2018-11-28
- **Final completion:** 2018-11-28
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-03-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117362, "Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02117362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*